Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

 
• By Jessica Merrill
opened yellow scissors over turquoise blue background
Biogen may have cost cuts ahead in 2021 • Source: Shutterstock

More from Strategy

More from Business